BioNTech's (NASDAQ:BNTX) investors will be pleased with their massive 749% return over the last five years
While the best companies are hard to find, but they can generate massive returns over long periods. To wit, the BioNTech SE ...
AI and the epistemic shift in scientific inquiry
AI’s predictive power needs to be balanced with a continued commitment to causal understanding and theoretical depth ...
Autolus Therapeutics (AUTL): High-Growth UK Stock in Cancer Therapy
We recently published a list of 8 High Growth UK Stocks to Invest In. In this article, we are going to take a look at where ...
pharmaphorum5d
Pfizer: Pharma needs a business strategy for a digital world
Its chief digital and technology officer Lidia Fonseca offered a fascinating insight into how one biggest ... the pandemic (alongside the likes of BioNTech, Moderna and AstraZeneca) – has ...
The New York Times29d
Take It From a Scientist. Facts Matter, and They Don’t Care How You Feel.
For both the Pfizer-BioNTech and Moderna mRNA vaccines ... If anyone’s mind changes, it will be on the basis of his or her own insight, not from verbal browbeating. Be prepared to admit the ...
The Canadian Press on MSN15d
For Canadians seeking a non-mRNA COVID vaccine, lack of Novavax shot is 'unfair,' advocates say
The federal government's decision to not provide Novavax's COVID-19 vaccine this respiratory virus season raises health ...
The Pharma Letter27d
The week in pharma: action, reaction and insight – week to September 2024
Also of note, Germany’s BioNTech presented mid-stage at ESMO for its BNT327 in lung cancer. In other significant developments, Organon announced it is acquiring Roivant Sciences subsidiary Dermavant ...
emjreviews.com22d
Navigating the COVID-19 Vaccination Landscape: The Post-pandemic Era – Interview with Three Key Opinion Leaders
Current CDC recommendations include one dose of an updated 2024–2025 COVID-19 vaccine (Pfizer-BioNTech, Moderna ... ranging from informed individuals who have a good insight to those who have little ...